Arcturus appoints Dr. Jing Marantz to board of directors effective Dec. 7, 2021

Arcturus Therapeutics Holdings Inc.

Dr. Marantz, SVP Head of Medical Affairs at Acceleron (Merck subsidiary), joins Arcturus board with immediate effect.
She brings experience from Alnylam, Alexion, Biogen; led global product launches for ONPATTRO and GIVLAARI.
Board also adopted new Code of Business Conduct and Ethics replacing prior code effective Dec. 7, 2021.
No other material changes; no financial impact disclosed.

item 5.02 item 5.05 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jing Marantz

director

ARCT · Arcturus Therapeutics Holdings Inc.

Effective: 2021-12-07
Filed: December 13, 2021, 6:59 PM ET

the Board subsequently appointed Dr. Jing Marantz to serve as a director of the Company, effective as of December 7, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jing Marantz was appointed as director at Arcturus Therapeutics Holdings Inc..

Action: appointed
Role: director

Exact text from the filing

the Board subsequently appointed Dr. Jing Marantz to serve as a director of the Company, effective as of December 7, 2021

View on SEC.gov

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-21-001738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.